VA John

431 total citations
25 papers, 346 citations indexed

About

VA John is a scholar working on Pharmacology, Pharmacology and Analytical Chemistry. According to data from OpenAlex, VA John has authored 25 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 9 papers in Pharmacology and 9 papers in Analytical Chemistry. Recurrent topics in VA John's work include Analytical Methods in Pharmaceuticals (9 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmaceutical studies and practices (5 papers). VA John is often cited by papers focused on Analytical Methods in Pharmaceuticals (9 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmaceutical studies and practices (5 papers). VA John collaborates with scholars based in United Kingdom, Switzerland and United States. VA John's co-authors include M. J. Kendall, Peter Lloyd, Adam Hulme, W. J. MacLennan, S.S. Davis, HJ Rogers, Neena Washington, KL Woods, W Theobald and J. Moppert and has published in prestigious journals such as Journal of Pharmaceutical Sciences, American Heart Journal and British Journal of Clinical Pharmacology.

In The Last Decade

VA John

25 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
VA John United Kingdom 11 74 74 72 71 65 25 346
P. J. Pentik�inen Finland 8 73 1.0× 70 0.9× 64 0.9× 81 1.1× 48 0.7× 9 379
P. Anderson Sweden 13 68 0.9× 53 0.7× 26 0.4× 70 1.0× 71 1.1× 20 413
Gregory M. Kochak Switzerland 12 89 1.2× 65 0.9× 38 0.5× 60 0.8× 105 1.6× 34 483
T.N. Calvey United Kingdom 15 70 0.9× 61 0.8× 61 0.8× 136 1.9× 57 0.9× 63 673
H Jaeger Germany 13 52 0.7× 126 1.7× 49 0.7× 102 1.4× 37 0.6× 58 487
A. Gérardin Switzerland 13 114 1.5× 79 1.1× 107 1.5× 153 2.2× 99 1.5× 25 630
Klaus D. Raemsch Germany 6 49 0.7× 71 1.0× 32 0.4× 54 0.8× 75 1.2× 8 376
V. A. John Switzerland 17 73 1.0× 115 1.6× 182 2.5× 158 2.2× 76 1.2× 34 716
J. Brès France 13 50 0.7× 111 1.5× 37 0.5× 157 2.2× 43 0.7× 23 455
M. Guerret France 13 52 0.7× 60 0.8× 30 0.4× 58 0.8× 37 0.6× 26 374

Countries citing papers authored by VA John

Since Specialization
Citations

This map shows the geographic impact of VA John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by VA John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites VA John more than expected).

Fields of papers citing papers by VA John

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by VA John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by VA John. The network helps show where VA John may publish in the future.

Co-authorship network of co-authors of VA John

This figure shows the co-authorship network connecting the top 25 collaborators of VA John. A scholar is included among the top collaborators of VA John based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with VA John. VA John is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
John, VA, Marı́a J. Ramı́rez, & William R. Good. (1996). Bioavailability of Estradiol from a New Estradiol Matrix Transdermal Delivery System (EMTDS. 0.1 mg/d) Compared with Estraderm" (0.1 mg/d). Menopause The Journal of The North American Menopause Society. 3(4). 228–229. 1 indexed citations
2.
Chan, Keith K. H., et al.. (1994). Effect of Food on the Relative Bioavailability of a Hypolipidemic Agent (CGP 43371) in Healthy Subjects. Journal of Pharmaceutical Sciences. 83(2). 264–266. 5 indexed citations
3.
4.
Lloyd, Peter, VA John, Mark Signy, & Stephen Smith. (1990). The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a metoprolol OROS system. American Heart Journal. 120(2). 478–482. 7 indexed citations
5.
Egger, Hanspeter, et al.. (1988). Disposition and metabolism of prinomide in laboratory animals.. Drug Metabolism and Disposition. 16(4). 568–575. 5 indexed citations
6.
7.
John, VA, et al.. (1985). A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.. British Journal of Clinical Pharmacology. 19(S2). 239S–244S. 13 indexed citations
8.
John, VA, et al.. (1985). Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.. British Journal of Clinical Pharmacology. 19(S2). 191S–195S. 8 indexed citations
9.
Kendall, M. J. & VA John. (1985). The role of clinical pharmacology in the development and evaluation of oral controlled‐release dosage forms.. British Journal of Clinical Pharmacology. 19(S2). 65S–67S. 2 indexed citations
10.
Woods, KL, et al.. (1985). A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer‐matrix and Oros dosage forms of oxprenolol in healthy volunteers.. British Journal of Clinical Pharmacology. 19(S2). 177S–184S. 11 indexed citations
11.
Warrington, SJ, et al.. (1985). Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration.. British Journal of Clinical Pharmacology. 19(S2). 219S–224S. 6 indexed citations
12.
Bennett, Joanne, I.D. Bradbrook, VA John, et al.. (1985). Single‐dose pharmacokinetic and pharmacodynamic comparison of polymer‐ matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.. British Journal of Clinical Pharmacology. 19(S2). 171S–175S. 7 indexed citations
13.
John, VA, et al.. (1985). Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report.. British Journal of Clinical Pharmacology. 19(S2). 203S–206S. 20 indexed citations
14.
John, VA, et al.. (1985). Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.. British Journal of Clinical Pharmacology. 19(S2). 163S–169S. 9 indexed citations
15.
John, VA, J. Paul Monk, John W. Hubbard, & W Theobald. (1983). Plasma profiles following single, oral, and rectal doses of phenylbutazone in healthy volunteers. Biopharmaceutics & Drug Disposition. 4(1). 95–99. 1 indexed citations
16.
John, VA, et al.. (1982). Bioavailability of phenylbutazone from a new enteric‐coated formulation with superior dissolution characteristics. Biopharmaceutics & Drug Disposition. 3(1). 67–74. 1 indexed citations
17.
18.
Kendall, M. J., et al.. (1978). Comparison of plasma and saliva levels of metoprolol and oxprenolol.. British Journal of Clinical Pharmacology. 5(3). 217–221. 28 indexed citations
19.
Beaumont, G, et al.. (1977). Efficacy, side-effects, plasma and blood levels of maprotiline (Ludiomil).. PubMed. 5 Suppl 4. 101–11. 7 indexed citations
20.
Kendall, M. J., M. Mitchard, Malcolm West, VA John, & Alan Ebbutt. (1976). Factors influencing the absorption of oxprenolol A pharmacokinetic study. European Journal of Drug Metabolism and Pharmacokinetics. 1(3). 155–160. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. J. Pentik�inen Breakdown of academic impact, for papers by P. Anderson Breakdown of academic impact, for papers by Gregory M. Kochak Breakdown of academic impact, for papers by T.N. Calvey Breakdown of academic impact, for papers by H Jaeger Breakdown of academic impact, for papers by A. Gérardin Breakdown of academic impact, for papers by Klaus D. Raemsch Breakdown of academic impact, for papers by V. A. John Breakdown of academic impact, for papers by J. Brès Breakdown of academic impact, for papers by M. Guerret
Rankless by CCL
2026